Castle’s DecisionDx-SCC Test Predicts Likelihood of Benefit From Adjuvant Radiation Therapy in SCC
Castle Biosciences DecisionDx-SCC can help identify cutaneous squamous cell carcinoma (SCC) patients who will benefit from adjuvant radiation therapy (ART), a new study in Future Oncology confirms. This is the second study to demonstrate the ability of the test to identify patients who are more or less likely to benefit from ART, confirmed in an […]